Faruqi & Faruqi Investigates Viatris Securities for Investors Amid Revenue Concerns

Investigating Viatris: A Shareholder Reminder

Faruqi & Faruqi, LLP, a prominent national securities law firm, is alerting investors regarding potential liabilities from Viatris, Inc. As the company faces accusations of making misleading statements that may have negatively impacted stock performance, the firm is actively encouraging affected investors to evaluate their legal options. This investigation centers around securities purchased between August 8, 2024 and February 26, 2025, coinciding with significant fluctuations in Viatris' stock price.

On February 27, 2025, Viatris disclosed disappointing financial results, linking its underwhelming forecast for fiscal year 2025 to issues arising from a warning letter from the U.S. Food and Drug Administration (FDA) concerning its Indore facility. After this announcement, Viatris experienced a stark decline in share price, plummeting approximately 15.21% from its closing price of $11.24 on February 26 to $9.53 on February 27.

The allegations against Viatris suggest executives failed to adequately inform investors about critical factors that could hinder the company's projected revenue and growth. Specifically, the class-action lawsuit claims that Viatris attempted to minimize the impact of a failed FDA inspection, which significantly affected the company’s ability to manufacture key products, including Lenalidomide. It also involves complications concerning distribution and an inability to persuade the FDA to reconsider regulatory exemptions for certain drugs.

Faruqi & Faruqi's jurisprudential approach emphasizes informing investors regarding their rights and promoting transparency throughout the legal process. With a long-standing track record of recovering substantial sums for shareholders since its establishment in 1995, the firm is positioned as a key player in holding corporations accountable for misrepresentation and negligence.

The firm reminds potential claimants of the June 3, 2025 deadline for applying to be the lead plaintiff in federal securities litigation against Viatris. Investors with relevant claims are urged to contact Faruqi & Faruqi's partner, Josh Wilson, directly via dedicated hotlines for further counsel and to strategize an appropriate response.

Any individuals with additional insights into Viatris’ business conduct—including whistleblowers, company insiders, or shareholders—are also encouraged to share their knowledge with the firm. Anonymity and confidentiality are assured for all communications.

In summary, the investigation by Faruqi & Faruqi, LLP emphasizes the vulnerability of corporate entities faced with legal scrutiny, especially in cases involving deceptive practices. For those affected by the recent developments surrounding Viatris, this represents a crucial opportunity to seek justice and redress through appropriate legal avenues. If you believe you have been adversely affected by these events, take action now and explore your options for potential recovery.